NCT06280495View on ClinicalTrials.gov

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Colorectal CancerLiver Metastases
Interventions
DRUG

Oxaliplatin

5 mg/m2 IV on day 1

DRUG

Fluorouracil

400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours

DRUG

Serplulimab

200 mg IV infusion on day 1

DRUG

Bevacizumab

5 mg/kg IV infusion on day 1

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER